Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Opus Genetics Inc. (OCUP:NASDAQ), powered by AI.
Opus Genetics Inc. is currently trading at $4.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Opus Genetics Inc. on Alpha Lenz.
Opus Genetics Inc.'s P/E ratio is -9.8.
“Opus Genetics Inc. trades at a P/E of -9.8 (undervalued) with modest ROE of -20.8%.”
Ask for details →Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics leverages advanced gene therapy techniques to design and deliver solutions that target the root causes of such vision disorders. By concentrating on the sensory system, particularly the eyes, they aim to restore vision or significantly stall disease progression. The company operates at the intersections of genetic research, clinical development, and ophthalmology, influencing the broader healthcare and medical research sectors. As part of a niche but crucial industry within biotechnology, Opus Genetics plays a significant role in pioneering treatments that could potentially transform the lives of those affected by genetic ocular diseases. Their work underscores the vital importance of breakthrough biomedical research and innovation in improving quality of life for patients with chronic and debilitating conditions.
“Opus Genetics Inc. trades at a P/E of -9.8 (undervalued) with modest ROE of -20.8%.”
Ask for details →